In recent years, the pharmaceutical market have seen a huge uptick in M&A activities. This year is certainly no exception. After much tribulation, the long-awaited $74 billion Bristol-Myers Squibb (BMY) merger with Celgene has begun to take place, and, over... Continue reading...